Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

Current Treatment of Younger 1L AML in 2024

Gautam Borthakur

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Secondary AML: Best Therapy Options

Weill Cornell Medicine Oncology & Hematology

P. Desai

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts

Prevention and Management of Post-SCT Relapse in Acute Leukemias

Vanderbilt University Medical Center (VUMC)

A. Jallouk

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray